A live webcast and a replay of the fireside chat will be available on Iradimed’s Investor page at https://www.iradimed.com/investors/events.
This year’s event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, thematic and industry panels, and company presentations by executive management from approximately 500 private and public companies in various growth sectors.
About
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only provider of a non-magnetic intravenous (“IV”) infusion pump system designed to be safe during MRI procedures. We were the first to develop an infusion delivery system that eliminates many dangers and problems during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other unique features to deliver anesthesia safely and predictably and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other unique features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The
For more information, please visit www.iradimed.com.
Media Contact:John Glenn Chief Financial OfficerIRADIMED CORPORATION (407) 677-8022 InvestorRelations@iradimed.com
Source:
2024 GlobeNewswire, Inc., source